We have received feedback from the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) that dosing may continue uninterrupted in ENVISION, study SRP-9001-303.

Pharma FDA rejection of extended dosing interval is another piece of bad news for Regeneron’s Eylea HD By Kevin Dunleavy Apr 21, 2025 8:45am Regeneron Pharmaceuticals Eylea Roche FDA ...

BOSTON -- Some equations used to calculate estimated glomerular filtration rate (eGFR) may alter chemotherapy dosing in cancer patients, a prospective study indicated.

Vancouver, British Columbia-- (Newsfile Corp. - February 6, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative ...

31 Jan 2025 The U.S. Food and Drug Administration approved Eisai and Biogen’s application for IV maintenance dosing of lecanemab on January 27. Previously, the label called for biweekly IV dosing. The ...

The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the monthly intravenous (IV) maintenance regimen of Leqembi ® (lecanemab-irmb) for ...

The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer disease (AD), enabling a transition from biweekly to once-every-4-week ...

Among patients with hepatic cirrhosis, carvedilol better controlled portal hypertension (PH) than propranolol, according to study results published in the Journal of Clinical Gastroenterology. Portal ...

Rice University. "Bioengineers shed light on dosing challenges for cancer immunotherapy." ScienceDaily. ScienceDaily, 6 November 2024. <www.sciencedaily.com / releases / 2024 / 11 / 241106132329.htm>.

Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients experiencing potentially serious brain swelling, according to interim results of a ...

Oncology/Hematology > Other Cancers Carvedilol No Help in Preventing Heart Failure in Childhood Cancer Survivors — While safe, the results do not support use of the drug in anthracycline-exposed ...

Once on study, patients took low doses of carvedilol or equivalent placebo for 2 years. The carvedilol group started at a dose of 3.125 mg, which was increased to 12.5 mg per day.